Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology
8:521–523 © 1995 Raven Press, Ltd., New York

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology Volume 8, 1995

Author Index

Abrams DI, 45
Adams J, 373
Ades EW, 64
Ajuluchuku EU, 315
Allemon M-C, 188
Allen S, 83
Anderson DJ, 236
Anderson R, 289
Arbeit RD, 195
Armengaud B, 91
Asch S, S45
Aseltyne WJ, S11, S85
Athale UH, 96
Averill L, 107
Aviñó MJ, 297
Avramis VI, 1

Barditch-Crovo P, 313
Bast M, 348
Batchelor B, 195
Bath GE, 399
Baumberger C, 358
Beall G, 279
Beauchamp D, 227
Becker P, 386
Bélec L, 212
Benito MJ, 266
Bennett CL, 373
Bennett RL, 373
Benson CA, 486
Berger J, 466
Bergerson MG, 227
Berry SH, 253
Bertazzoni U, 516
Besemer D, 446
Biberfeld G, 182
Bird IA, 134
Biteau N, 330
Blanche S, 188
Blattner WA, A25, 215
Blick G, 279
Bolúmar F, 297
Boota A, 152
Bozzette SA, S45, 253, 345
Brathwaite AR, 215
Bredberg-Rådén U, 182
Brindle RJ, 195
Brunton J, 348
Buchbinder SP, 58
Burge SK, 302
Burns SM, 399
Buvé A, 511
Bwayo J, 195
Byrne GE Jr, 466
Byrnes JJ, 466

Cabral L, 466
Cagnon L, 427
Cai J, 455
Calabrese LH, 279
Carael M, 83
Carles G, 420
Carlson JO, 124
Casoli C, 516
Cassileth B, 373
Cattaneo E, 516
Chambrin V, 188
Chang SW, 58
Charlebois ED, 45
Chavance M, 91
Cheeseman SH, 141, 152
Chen K, 66
Chenadec J Le, 188
Child C, 45
Chintu C, 96
Chout R, 91
Cloutier M, S11
Cohen EA, 10
Comans TW, 64
Conant MA, 279
Concha-Bermejillo A de la, 124
Coodley GO, 213
Courpotin C, 188
Craib KJP, 474
Cucchiarini M, 427
Cunningham P, 411

Dabis F, 506
Dando S, 107
Daugherty SR, 486
Davies AG, 399
Davis G, 289
Dax EM, 411
Dazza M-C, 511
Dean L, 208
Deicher H, 329
Dekaban GA, 134, 437
Delaporte E, 511
DeMartini JC, 124
Désormeaux A, 227
Díez J, 266
Doglio A, 427
Doignon F, 330
Doll LS, 58
Dominy NJ, 399
Dramé L, 315
Drew WL, 289
Dunagan WC, 51

Elem B, 96
Ellis ME, 101
Embree JE, 176
Eni EU, 315
Essex M, 23
Ewert DP, 461

Fallatah S, 101
Farnham P, 392
Fernández-Cruz E, 266
Ferrer L, 297
Fichtenbaum CJ, 51
Figueroa JP, 215
Firtion G, 188
Fischl MA, 152
Fisher A, 279
Fleury HJA, 330
Fong S-J, 446
Fortgang IS, 365
Fournel JJ, 315
Freedberg KA, 292
Fretz C, 315
Friborg J, 10
Fries JF, 392

Galai N, 66
Gallagher KM, 292
Galpin JE, 279
García-Ramos G, 23

George L, 373
Georges D, 107
Gérard Y, 420
Gessain A, 315, 420
Gherardi RK, 212
Gilks CF, 195
Gill P, 455, 466
Gilman SC, 373
Giordanengo V, 427
Giordano J, 75
Goeman J, 511
Goldberg D, 107
Goldstein G, 279
Gonzalez B, 266
Göttlinger H, 10
Graham NMH, 66
Grankvist O, 182
Greenberg A, 466
Greenough TC, 141
Grésenguet G, 212
Grim JA, 273
Grossman HA, 279
Guillot F, 188

Haimovici F, 236
Halim MA, 101
Hall D, 141
Harrington WJ Jr, 466
Harry TO, 315
Haseltine WA, A25, 10
Hattox SE, 141
Havlir D, 141
Hawkes SJ, 214
Hayes PS, 461
Hayes R, 215
Hays RD, 253
He YD, 496
Healey DS, 411
Henzel D, 511
Hernández-Aguado I, 297
Herndier BG, 379
Hessol NA, 58
Heyward W, 511
Highsmith AK, 64
Hillman AL, S23
Hirsch RL, 279
Hirschel B, 358
Hoffman RE, 406
Hoo B, 446
Hoogestraat L, 329
Hudes E, 83
Huerta E, 23
Hughes WT, 247

Iobidze M, 480
Irvine B, 446
Iwanik J, 386

Janssen R, 75
Jarvis JN, 480
Jeannel D, 315
Jenniskens F, 176
Johnson WD Jr, 214
Jung B, 455

Kahn JG, S53
Kahn JO, S1
Kaiser L, 358
Kanouse DE, 253
Kaplan LD, 45
Karita E, 83
Karlsson K, 182
Karter AJ, 199
Karter DL, 199
Kaslow RA, 496
Kass PH, 199
Katz MH, 58
Kawo G, 182
Kazimoto T, 182
Keddy K, 386
Kelley KF, 102
Kemper R, 466
Kern DG, 446
Kessler HA, 486
Kimari J, 195
Kirby AJ, 496
Kislak JW, 199
Knowlton DL, S74
Kokka R, 446
Kolberg J, 446
Kourouma K, 315
Krause R, 134
Kurth R, 217
Kwock R, 1

Ladha A, 10
Laga M, 511
Lalezari J, 289
Lang W, 289
Law R, 455
Lawrence DM, S4
Le N, 474
Le TN, 474
Lebow JM, 292
Lederman MM, 107
Lefebvre J-C, 427
Leigh JP, 392
Lepère J-F, 420
Lessard C, 227
Levi J, S80
Levinton C, 348
Lewis E, 75
Liautaud B, 214
Lieb L, 461
Lietman P, 313
Lin G, 455
Liu X, 1
Louie S, 455
Low NM, 214
Lubeck DP, 392
Luft H, S53
Lunardi-Iskandar Y, 455
Lyamuya E, 182

Makabi-Panzu B, 227
Makadon HJ, S85
Malani H, 75
Margolick JB, 66, 496
Martin DJ, 386
Mascola L, 461
Masood R, 455
Masquelier B, 330
Massawe A, 182
Mayaux M-J, 188
Mbena E, 182
McArthur JC, 273
McGrath MS, 379
McLaughlin MM, 141
Meillet D, 212
Mellon RL, 214
Meng T-C, 152
Mertens T, 83
Meyer I, 208
Meyerson LA, 279
Mhalu F, 182
Michelet C, 330
Mikl J, 102
Miller G, 466
Miller GB, 386
Miller LA, 406
Miner RC, 289
Mirda MI, 45
Monplaisir N, 91
Montaner JSG, 474
Moore RD, 365
Moreau J-P, 420
Morlat P, 330
Morris J, 215
Morton SC, 345
Moses S, 176
Msemo G, 182
Müller MJ, 329
Muñoz A, 66, 496
Muradali D, 348
Mwachari C, 195
Myers M, 141

Nagelkerke NJD, 176
Neff JA, 302
Neisson-Vernant C, 91
Nelson G, 321
Neuwald P, 446
Niekerk ABN van, 386
Nord J, 199
Norley S, 217
Northfelt DW, 45
Novak IS, 23
Nsengumuremyi F, 83
Nys N, 321
Nzila N, 511

Obregón E, 266
O'Brien TR, 104
Ockenga J, 329
O'Connell JJ, 292
Oddleifson S, 292

O'Malley P, 58
O'Shaughnessy MV, 474
Oshima KH, 64
Ozbay B, 386

Pachl C, 446
Padgug RA, S67
Pape JW, 214
Park I-W, 335
Patil PS, 96
Patterson C, 199
Pellegrin I, 330
Peneau C, 420
Pennypacker C, 321
Perelson AS, 321
Pérez-Hoyos S, 297
Perrin LH, 358
Peruga A, 215
Peters A, 399
Petrakis T, 152
Phair JP, 496
Piot P, 511
Pizzo PA, 30
Plummer FA, 176
Poiesz B, 466
Poland SD, 437
Pottage JC Jr, 486
Poulin L, 227
Powderly WG, 51
Power C, 273

Quist D, 91

Rabin M, 466
Rabkin JG, 204
Rabkin R, 204
Ragnaud J-M, 330
Rappaport D, 348
Rebagliato M, 297
Reeves MW, 461
Reingold A, 75
Resnick L, 152
Reyn CF von, 195
Rice GPA, 437
Richardson AM, 399
Richman DD, 141, 152
Rieder MJ, 134
Rinaldo CR, 496
Rivera VM, 23
Rodrique D, 373
Rossi P, 161
Rouzioux C, 188
Ruffault A, 330
Ruiz I, 297
Ryan A, 386
Rymer L, 386

Salemi M, 516
Salit I, 348
Schechter MT, 474
Schietinger H, S80
Schmelzer R, 107
Seage GR III, 292
Seed J, 83
Selberg O, 329
Selnes OA, 273
Sempere MJ, 266
Serufilira A, 83
Sessler DI, 321
Sha BE, 486
Shalekoff S, 386
Sheremata W, 466
Sheridan PJ, 446
Shiramizu BT, 379
Siegel F, 217
Silvester C, 411
Sim JGM, 386
Smith MD, S1, S11, S53
Smith PF, 102
Snodgrass S, 466
So Y, 75
Sodroski J, 335
Sole GJ, 386
Solorzano MM, 1
Spector SA, 141, 152
Spence D, 348
Spencer NE, 406
Stampone P, 279
Stein DS, 141
Stempien M, 446
St-Louis M, 511
Sullivan JL, 141
Süttmann U, 329
Svobodova V, 313

Taylor H, 480
Thé G de, A26, 315, 420
Todd JA, 446
Tortevoye P, 420
Tremblay M, 227
Tricoire J, 188
Trujillo JR, 23
Tuppin P, 420

Ucar A, 466
Urassa E, 182
Urassa W, 182
Urbanski PA, 486
Urdea MS, 446
Ureta VA, 315
Ureta-Vidal A, 420

Van de Perre P, 83
Vermund SH, 215
Vigneron NC, 188
Vilmer E, 188
Viscovic T, 386
Visscher BR, 496
Vittinghoff E, 75
Vlahov D, 66
Voight W, 466
Volberding PA, A25

Wagner G, 204
Walmsley S, 348
Wang F, 75
Weilbach CN, 386
Westmoreland T, S7
Whitcomb CC, 466
Wilfert CM, 30
Wilson IB, S31
Woodward TM, 124
Woolf M, 386
Wright B, 152
Wu AW, 253
Wu S, 1

Yarrish R, 199
Yeghiazarian T, 446
Yerly S, 358

Zabay JM, 266
Zheng YM, 315

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology
8:524–528 © 1995 Raven Press, Ltd., New York

Journal of Acquired Immune Deficiency Syndrome and Human Retrovirology Volume 8, 1995

Subject Index

Acyclovir, failure of high-dose oral, 289
Adult T-cell leukemia/lymphoma, 466
Adverse drug reactions, 134
Africa
  HIV/tuberculosis coinfection in, 386
  HTLV-I infection of prostitutes and pregnant women in, 511
  Kaposi's sarcoma incidence in children of, 96
  mother-to-child HIV-1 transmission in, 182, 506
  regional differences in retroviral infections in, 315
African green monkey, SIV_{agm} infection in, 217
AIDS
  comparative study of neurologic manifestations of, 23
  flank abscess and, 315
  heterosexual, 104
  in homeless, 292
  hypercalcemia associated with cytomegalovirus in, 101
  incidence proportion and risk factors for, 75
  interleukin-1 and interleukin-1 receptor antagonist effects on, 455
  Pneumocystis carinii pneumonia complicating, 348
  predicting progression to, 266
  surveillance of invasive cervical cancer cases of, 102
  vitamin A deficiency in, 199
  WHO staging system for, 474
Alcohol consumption, sexual behavior and, 302
America, mother-to-child transmission of HIV-1 in, 506
Animal models, response to lentiviruses in, 116
Anthropometry, in HIV-infected outpatients, 239
Antibody-dependent cellular cytotoxicity, 217
Anti-HIV-1/HIV-2 enzyme immunoassay, 411
Antiviral chemotherapy, 330
ATHOS, 392
Atovaquone tablets, for *Pneumocystis carinii* pneumonia, 247
AZT, *See* Zidovudine

Bacteremia, in hospitalized HIV-infected patients, 51
Blood banks, implications of HIV and STDs association for, 214
Blood transfusions, in children, 96
Blood-borne virus, viral filtration of, 64
Blood-brain barrier, HIV-1 infection and, 437
Body composition, in HIV-infected outpatients, 239
Book Reviews
  AIDS and the heterosexual population, 104
  The myth of heterosexual AIDS: how a tragedy has been distorted by the media and partisan politics, 104
Boston, AIDS among homeless in, 292
Brain lymphoma, comparative study of, 23
Branched DNA signal amplification assay, 446
Breastfeeding
  in developing countries, 176
  HIV transmission and, 161

Caesarean section, in perinatal transmission prevention, 161
Cancer, invasive cervical, 102
Care standards, for HIV disease, S45
$CD4^+$ T-lymphocyte count
  for asymptomatic HIV, 279
  in HIV/tuberculosis coinfection, 386
  in predicting progression to AIDS, 266
$CD4^+$ T-lymphocytes
  degradation of, 427
  longitudinal patterns of, 496
Central nervous system toxoplasmosis, incidence proportion and risk factors with diagnosis of, 75
Cervical cancer, invasive in AIDS surveillance, 102
Cervicovaginal secretions, semen in, 236
Chicago, HIV in women of, 486
Children
  Kaposi's sarcoma incidence in, 96
  markers of HIV disease progression in, 30
Circumcision, HIV risk and, 83
Clinical grade, HIV/HTLV-I coinfection and, 91
Clonal HIV form, in early Kaposi's sarcoma, 379
Colorado, confidential HIV tests sites in, 406
Combination therapy
  for HIV, 141
  with recombinant human soluble CD4-immunoglobulin G and Zidovudine, 152
Complement activation, in early congenital HIV, 480
Confounding factors, in HIV diagnosis, 91
Contamination, viral filtration for, 64
Corticosteroids, adjunctive use of for *Pneumocystis* pneumonia, 345, 348
Cryptococcal meningitis, incidence proportion and risk factors with diagnosis of, 75

Cytomegalovirus
acyclovir for viruria of, 289
comparative study of, 23
hypercalcemia associated with, 101
Cytopathogenicity, of ovine lentivirus, 124

Deletion mutations, SIV gene, 335
Delta value, for anti-HIV-1/HIV-2 enzyme immunoassay, 411
Dementia
AIDS complex, 23
HIV-1, 273
Developing countries, breastfeeding by HIV-1-infected mothers in, 176
Diagnostic screen, HIV-1 dementia, 273
Didanosine
decreased viremia with, 358
genotypic evolution of HIV-1 isolated after use of, 330
Diet, for AIDS patients, 199
Disease control, confidential HIV testing and, 406
Drug users
AIDS among, 292
HIV in, 399
HIV-1 incidence and prevalence trends in, 297
HTLV-II infection in, 516
predicting progression to AIDS in, 266

Economic cost, of HIV infection, 392
Edinburgh, HIV in injecting drug users of, 399
Endothelial cells, HIV-1 infection of, 437
Enzyme immunoassay, anti-HIV-1/HIV-2, 411
Epidemic, Kaposi's sarcoma incidence in Zambian children and, 96
Epidemiology, of AIDS-related disease, 75
Ethnicity, sexual behavior and, 302
Europe, mother-to-child transmission of HIV-1 in, 506
Euthyroid sick syndrome, 212

Fibroblast growth factor, basic, 379
Filtration, HIV removal by, 64
Flank abscess, 315
Florida, HTLV-I in, 466
Forensics, semen detection in, 236
France, perinatal HIV-1 transmission in, 188
French Guiana, maternal risk factors for HTLV-I infection, 420
French West Indies, HIV/HTLV-I coinfection and clinical grading in, 91
Functional analysis, SIV gene, 335

Ganciclovir-resistant cytomegalovirus, 289
Genetic variation, of ovine lentivirus, 124
Genital ulcers, HIV-1 risk and, 214
Genotypic evolution, of HIV-1 isolates, 330
Glutathionine deficiency, 313
Glycoprotein-CD4 interaction, 427

Guinea, regional differences in retroviral infections in, 315

Haiti, HIV and STDs in, 214
Health care costs, indirect, 392
Health insurance, in HIV-infected men, 58
Health status assessment instrument, derivation and properties of, 253
Het inactivation, in vivo, 321
Heterosexual AIDS, myth of, 104
Heterosexual population, AIDS in, 104
HIV-1 dementia
incidence proportion and risk factors with diagnosis of, 75
screening for, 273
HIV-1 infection
cervicovaginal lavage for, 236
decreased viremia with didanosine treatment of, 358
genotypic evolution of, 330
of human brain-derived microvascular endothelial cells, 437
induction of, 427
long-term survivors with, 496
markers for mother-to-child transmission of, 182
maternal factors in perinatal transmission of, 188
rates of mother-to-child transmission of, 506
regional differences in West Africa, 315
RNA quantification of, 446
trends in incidence and prevalence of, 297
Vpu protein of, 10
HIV-2 infection
induction of, 427
regional differences in West Africa, 315
HIV surveillance, in Edinburgh drug users, 399
HIV test sites, anonymous and confidential, 406
HIV wasting syndrome, 212
Homeless, AIDS among, 292
Homosexual men
HIV marker change in, 66
HIV prevalence and sexual behavior in, 208
Hospital admission, for HIV, 365
Hospitalized patients, bacteremia in, 51
Host genetics, response to lentiviruses and, 116
Human immunodeficiency virus
asymptomatic, 279
bacteremia with, 51
capitated alternative to care for, S74
clonal form in early Kaposi's sarcoma, 379
disseminated *Mycobacterium avium* infection in, 195
early congenital, 480
health insurance and use of medical services for, 58
health status assessment in, 253
hospital admissions for in Maryland, 365
human T-lymphotropic virus-I coinfection and clinical grade of, 91
induction of, 427
in injecting drug users, 399
in vivo heat inactivation of, 321
in isogeneic twin lamb models, 116
Kaposi's sarcoma incidence in children and, 96
long-term survivors with, 496

low testosterone levels in men with, 204
male circumcision and risk of, 83
malnutrition and wasting in, 239
markers of progression in children, 30
monitoring progression of, 446
mother-to-child transmission, 176
mother-to-child transmission rates of, 506
nevirapine with Zidovudine for, 141
L-2-Oxothiazolidine-4-carboxylic acid effect on, 107
Pneumocystis carinii pneumonia complicating, 348
prevalence in New York City gay men, 208
prevention of perinatal transmission of, 161
regional differences in West Africa, 315
removal by filtration, 64
seroconverters of, 66
serotype distribution in Los Angeles county, 461
sexually transmitted disease and in Haiti, 214
sulfonamide-reactive metabolite toxicity in, 134
vaccine trials for, 214
with tuberculosis, 386
waiting times in modified WHO staging system for, 474
in women, 486
workday loss from, 392
zidovudine and rCD4-IgG, 152
Human T-cell lymphotropic virus
regional differences in West Africa, 315
sulfonamide-reactive metabolite toxicity in, 134
Human T-cell lymphotropic virus type I
clinical spectrum of in south Florida, 466
coinfection, 91
maternal risk factors for, 420
sexual transmission of, 511
Human T-cell lymphotropic virus type II, in injecting drug users, 516
Hydroxylamines, 134
Hypercalcemia, with cytomegalovirus infection, 101

Immune complexes, in early congenital HIV, 480
Immune thrombocytopenic purpura, continuous low-dose interferon-α therapy for, 45
Immunization, passive, 161
Inactivated virus immunogen, against SIV_{agm}, 217
Incidence proportion, for AIDS patients, 75
Incubation period, for HIV-1 infection, 496
Injecting drug users
AIDS among, 292
HIV in, 399
HIV-1 incidence and prevalence trends in, 297
HTLV-II infection in, 516
predicting progression to AIDS in, 266
Interferon-α, continuous low-dose therapy, 45
Interleukin-1, effects in AIDS-Kaposi's sarcoma, 455
Interleukin-2 receptor alpha chain, L-2-oxothiazolidine-4-carboxylic acid effect on expression of, 107
Interleukin-1 receptor antagonist, effects in AIDS-Kaposi's sarcoma, 455
Intracranial tuberculoma, comparative study of, 23
Intravenous catheters, bacterial infections with, 51
Isogeneic twin lambs
ovine lentivirus strain changes in, 124
responses to lentiviruses, 116
Italy, HTLV-II infection in injecting drug users of, 516

Jamaica, rising HIV-1 prevalence in STD clinic attenders in, 214

Kaposi's sarcoma
clonal form of HIV in early, 379
interleukin-1 and interleukin-1 receptor antagonist effects on, 455
in Zambian children, 96
Kenya, *Mycobacterium avium* infection in HIV-infected patients in, 195

Learning curve, for *Pneumocystis carinii* pneumonia treatment, 373
Lentivirus
biological and genetic changes in, 124
twin lamb responses to, 116
Letters to Editor
Apparent deficiency of glutathionine in the PBMC's of people with AIDS depends on method of expression, 313
Association of HIV and STDs in Haiti: Implications for blood banks and HIV vaccine trials, 214
Flank abscess in AIDS and tuberculosis, 315
Hypercalcemia associated with cytomegalovirus infection in an AIDS patient, 101
Increased tumor necrosis factor-α serum levels in patients with HIV wasting syndrome and euthyroid sick syndrome, 212
Increased tumor necrosis factor-α serum levels with HIV wasting syndrome and euthyroid sick syndrome (author's reply), 213
Regional differences in human retroviral infections HIV-1, HIV-2, and HTLV-I/II in rural Guinea (West Africa), 315
Review of invasive cervical cancer cases for AIDs surveillance, 102
Rising HIV-1 prevalence in STD clinical attenders in Jamaica, 214
Rising HIV-1 prevalence in STD clinical attenders in Jamaica (authors' reply), 215
Liberal/conservative orientation, sexual behavior and, 302
Linked risk factor questionnaires, among drug users, 399
Liposomal ddC, uptake and binding of, 227
Listeria monocytogenes infection, 461
Los Angeles, *Listeria monocytogenes* infection and HIV infection in, 461
L-2-oxothiazolidine-4-carboxylic acid (Procysteine), effects on HIV, 107
Lymphoid interstitial pneumonia, degree of, 116
Lymphoma, primary brain, 23

Malnutrition, incidence and prognostic value of, 239
Markers

changes in after HIV-1 seroconversion, 66
of HIV disease progression in children, 30
for mother-to-child transmission of HIV-1, 182
Markov model, 474
Maryland, hospital admissions of HIV-infected patients in, 365
Maternal immunity, HIV perinatal transmission and, 161
Maternal risk factors, in perinatal HIV-1 transmission, 188
Maternal transmission, breastfeeding and, 176
Mathematical model, of in vivo heat inactivation of HIV, 321
Media, on heterosexual AIDS, 104
Megestrol, low testosterone levels and, 204
Metabolism, in HIV-infected outpatients, 239
β_2-Microglobulin
in HIV-1 transmission, 182
serum levels of, 266
Minimental State Exam, 273
Molecular subtypes, in HTLV-II infection, 516
Monitoring, disease progression, 446
Mother-to-child transmission, 161, 188
markers for, 182
rates of for HIV-1 infection, 506
Mutations
of HIV-1 isolates, 330
of SIV genes, 335
Mycobacterium avium, in HIV-infected patients, 195
Myelopathy, HTLV-I-associated, 466

nef gene, functional analysis of, 335
Neoplasia, sequential, 379
Neuropathy, comparative study of, 23
Neuropsychology, HIV dementia scale in, 273
Neutralizing antibody, SIV_{agm}, 217
Nevirapine, phase I/II evaluation of, 141
New York City, HIV prevalence and sexual behavior in gay men in, 208
New York State health insurance, S67
NF-kB binding, procysteine and, 107
Noir Marron population, maternal risk factors for HTLV-I infection, 420
Nonnucleoside reverse transcriptase inhibitor for HIV, 141
in perinatal transmission prevention, 161
Nutrition, for AIDS patients, 199

Oncogenesis, novel model of, 379
Outpatient services, health insurance and in HIV-infected men, 58
Ovine lentivirus
biological and genetic changes in, 124
twin lamb responses to, 116

p24 antigen, 266
in asymptomatic HIV, 279
in HIV-1 transmission, 182
Partner notification, at anonymous and confidential HIV test sites, 406
Passive immunoglobulin transfer, against SIV_{agm}, 217
Pediatrics, Kaposi's sarcoma incidence in, 96
Perinatal transmission
maternal factors in, 188
prevention of, 161
Pharmacokinetics
of Zidovudine and nevirapine, 141
of Zidovudine and rCD4-IgG, 152
Plasma, HIV-1 RNA in, 446
Pneumocystis carinii pneumonia
adjunctive corticosteroid treatment of, 345, 348
atovaquone tablets for, 247
learning curve for AIDS-related, 373
prophylaxis for, 58
Point mutations, SIV genes, 335
Politics
heterosexual AIDS and, 104
Polymerase chain reaction
with didanosine therapy, 358
of HIV-1 endothelial cell infection, 437
inverse, 379
in predicting HIV-1 transmission, 182
of RT gene, 330
Pregnancy
HIV perinatal transmission prevention and, 161
HTLV-I infection during, 511
HTLV-I risk factors during, 420
Prevention, of HIV perinatal transmission, 161
Prisoners, drug use and HIV in, 399
Procysteine, effects on HIV and interleukin-2 expression, 107
Prognosis
in children, 30
in HIV-infected outpatients, 239
Progression
of asymptomatic HIV, 279
of HIV in women, 486
serum β_2-microglobulin in predicting, 266
WHO staging system for, 474
Prostitutes, HTLV-I infection among, 511
Proviral DNA, with didanosine therapy, 358
Public health, confidential HIV testing and, 406

Quality of life, assessment in HIV-infected patients, 253

Recombinant human soluble CD4-immunoglobulin G, with zidovudine, 152
Referral, selective, 373
Regional differences, in retroviral infections, 315
Resistance, to zidovudine and didanosine, 330
Retinol, deficiency of in AIDS patients, 199
Retroviral infections, regional differences in West Africa, 315
Reverse transcriptase (RT) gene, mutation of, 330
Risk, politics of, S7
Risk behaviors, predictors of, 302
Risk factors
for AIDS patients, 75

drug use as, 399
for maternal HTLV-I infection, 420
in perinatal HIV-1 transmission, 188
with sexually transmitted disease, 214
Rwanda, male circumcision and risk of HIV in, 83

Screening test, for HIV-1 dementia, 273
Semen, in cervicovaginal secretions, 236
Sepsis, in hospitalized HIV-infected patients, 51
Seroconversion, evaluation of, 411
Seroconverters, marker changes and, 66
Serotypes, distribution in Los Angeles county, 461
Sexual behavior
in gay men, 208
high-risk and HTLV-I infection, 511
predictors of, 302
Sexual transmission, HTLV-I, 511
Sexually transmitted disease
HIV and in Haiti, 214
male circumcision and, 83
Signal amplification, 446
Simian immunodeficiency virus genes, 335
SIV_{agm}, protection against, 217
Spain, HIV-1 infection in intravenous drug users in, 297
Staging system, for HIV infection, 474
Statistical models, of HIV-1 survivors, 496
STD clinics, rising HIV-1 prevalence in, 214
Strain phenotypes, of ovine lentivirus, 124
Substance abuse, HIV marker change in, 66
Sulfonamide-reactive metabolites, toxicity of, 134
Survival
analysis in HIV-infected outpatients, 239
for HIV-infected women in Chicago, 486
long-term, with HIV-1 infection, 496
Syncytium formation, HIV-1 Vpu protein and, 10

Tanzania, mother-to-child HIV-1 transmission in, 182
T-cells
subsets of, 66, 182
Zidovudine resistance in, 1
Testosterone, low levels in men with HIV, 204
Thymidine kinase gene, Zidovudine resistance and, 1
Thymopentin, safety and efficacy of, 279
Toxoplasmosis, incidence proportion and risk factors with diagnosis of, 75
Transcriptase, reverse, 1
Transmission
breastfeeding and, 176
markers for, 182
mother-to-child, 161, 182, 188, 506
perinatal, prevention of, 161
sexual, 511
Traumatic sex, HIV-1 risk and, 214
Tuberculosis
flank abscess and, 315
with HIV infection, 386
Tumor necrosis factor-α, increased serum levels of, 212

Vaccine, SIV_{agm}, 217
Vaginal lavage, in perinatal transmission prevention, 161
Vertical transmission, predictive markers for, 182
Veterans Affairs hospitals, *Pneumocystis carinii* pneumonia cases in, 373
Viral filtration, HIV removal by, 64
Viral release, of HIV-1 Vpu protein, 10
Viremia, early and prolonged decreased of in HIV-1, 358
Viruria, cytomegalovirus, 289
Vitamin A deficiency, AIDS-related, 199
vpr gene, functional analysis of, 335
Vpu protein, HIV-1, 10
vpx gene, functional analysis of, 335

Waiting time estimates, 474
Wasting, incidence and prognostic value of, 239
West Africa, regional differences in retroviral infections in, 315
WHO staging system, waiting times in, 474
Women, HIV infection in, 486
Workday loss, in HIV patients, 392

Zaire, HTLV-I infection of prostitutes and pregnant women in, 511
Zambia, Kaposi's sarcoma incidence in children of, 96
Zidovudine
genotypic evolution of HIV-1 isolated after use of, 330
health insurance and use of, 58
nevirapine with, 141
in perinatal transmission prevention, 161
with recombinant human soluble CD4-immunoglobulin G, 152
resistance to in Jurkat T cells, 1
safety and efficacy of, 279